Toru Akiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Toru Akiyama has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Kimura
Department of Orthopaedics, Jichi Medical University, Shimotsuke, Japan
1 shared publication - Hirotaka Chikuda
Department of Orthopedic Surgery, Graduate School of Medicine, Gunma University, 3-39-22 Showa-Machi, Maebashi 371-8511, Japan
1 shared publication - Kentaro Hayakawa
Department of Orthopaedics and Spine Surgery, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi 173-0015, Japan
1 shared publication - Makoto Kurano
Department of Clinical Laboratory Medicine, The University of Tokyo Hospital, Bunkyo 113-0033, Japan
1 shared publication - Masahiko Sumitani
Department of Pain and Palliative Medicine The University of Tokyo Hospital Tokyo Japan
1 shared publication - Reo Inoue
Surgical Center, The University of Tokyo Hospital, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (6) , 573
Lysophosphatidic Acid 18:0 sn-1 in Cerebrospinal Fluid as a Potential Biomarker of Depressive Symptoms in Patients with Neuropathic Pain
Background/Objectives: Lysophosphatidic acid (LPA) is a bioactive lipid mediator implicated in neuropathic pain (NP). Depressive symptoms frequently accompany NP and adversely affect outcomes, yet objective biomarkers remain limited. This study aimed to identify cerebrospinal fluid (CSF) LPA molecular species associated with depressive symptoms in patients with NP. Methods: CSF samples were obtained from 48 patients, and LPA species, including positional isomers (sn-1 and sn-2), were quantified using liquid chromatography–tandem mass spectrometry. Depressive symptoms were assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Statistical analyses were performed to evaluate associations among depressive symptoms, clinical variables, and LPA species. Results: CSF LPA18:0 was significantly associated with HADS-D scores (r = 0.380, p = 0.010), with the strongest association observed for the sn-1 isoform (r = 0.385, p = 0.009). In multivariable analysis, LPA18:0 sn-1 remained independently associated with depressive symptoms, alongside pain intensity and pain catastrophizing (R2 = 0.386). Structural equation modeling supported an association between LPA18:0 sn-1 and depressive symptoms independent of pain-related factors. Conclusions: These findings suggest that CSF LPA18:0 sn-1 may be associated with a biological dimension of depressive distress and may represent a candidate biomarker of depressive distress in NP. However, these findings should be interpreted cautiously, as the analyses were exploratory, and further validation in independent and longitudinal cohorts is warranted.
- 28 May 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (6) , 573
Open AccessLysophosphatidic Acid 18:0 sn-1 in Cerebrospinal Fluid as a Potential Biomarker of Depressive Symptoms in Patients with Neuropathic Pain
Background/Objectives: Lysophosphatidic acid (LPA) is a bioactive lipid mediator implicated in neuropathic pain (NP). Depressive symptoms frequently accompany NP and adversely affect outcomes, yet objective biomarkers remain limited. This study aimed to identify cerebrospinal fluid (CSF) LPA molecular species associated with depressive symptoms in patients with NP. Methods: CSF samples were obtained from 48 patients, and LPA species, including positional isomers (sn-1 and sn-2), were quantified using liquid chromatography–tandem mass spectrometry. Depressive symptoms were assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Statistical analyses were performed to evaluate associations among depressive symptoms, clinical variables, and LPA species. Results: CSF LPA18:0 was significantly associated with HADS-D scores (r = 0.380, p = 0.010), with the strongest association observed for the sn-1 isoform (r = 0.385, p = 0.009). In multivariable analysis, LPA18:0 sn-1 remained independently associated with depressive symptoms, alongside pain intensity and pain catastrophizing (R2 = 0.386). Structural equation modeling supported an association between LPA18:0 sn-1 and depressive symptoms independent of pain-related factors. Conclusions: These findings suggest that CSF LPA18:0 sn-1 may be associated with a biological dimension of depressive distress and may represent a candidate biomarker of depressive distress in NP. However, these findings should be interpreted cautiously, as the analyses were exploratory, and further validation in independent and longitudinal cohorts is warranted.